Haleon ups stake in China joint venture to 88%

Haleon said on Friday that it has agreed to buy an additional 33% interest in Tianjin TSKF Pharmaceutical - its joint venture in China - from its partners Tianjin Pharmaceutical Group (TPG) and Tianjin Pharmaceutical Da Ren Tang Group Corporation (DRTG) for RMB4,465m (circa£0.5bn).